Trump and Xi Temple of Heaven Visit Highlights Trade and Diplomacy Goals 
Dulles Airport Rebuild Plan Could Transform Washington’s Main International Gateway 
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia 
Asian Stocks Steady as Iran War Concerns Persist Ahead of Trump-Xi Summit 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
BlackRock-Led GCC Infrastructure Partnership Targets $30 Billion Investment 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Dollar Gains as Fed Rate Hike Bets Rise Ahead of Trump-Xi Summit 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Trump Faces Uphill Battle Seeking China’s Help on Iran Conflict 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
S&P Global Revises Mexico Credit Outlook to Negative Amid Rising Debt Concerns 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
SoftBank Shares Slide Despite Record Q4 Profit Fueled by OpenAI Investment 
Asian Currencies Slide as Indian Rupee Hits Record Low Amid Iran Tensions 
OpenAI Finds No Evidence of User Data Breach in TanStack npm Supply-Chain Attack 
In a landmark move, Samsung Biologics and Pfizer Inc. have entered into a strategic $409 million contract manufacturing organization (CMO) agreement. This record-setting deal enlists Samsung Biologics to produce a range of biosimilar drugs originally developed by Pfizer, furthering global access to essential medicines.
The Korea Times reported that under the contract, Samsung Biologics will manufacture biosimilars made by Pfizer. These are biopharmaceutical medical products that are identical to the original product, which means the Korean biotech firm will replicate certain drugs originally made by Pfizer.
The biosimilars that Samsung Biologics will produce for the New York-based pharmaceutical and biotechnology firm include medical drugs for inflammation, tumors, and the immune system. The company built its fourth production plant in Incheon, South Korea, recently, so it is likely to be used for the fulfillment of the said CMO agreement.
“We are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe,” Samsung Biologics’ president and chief executive officer, John Rim, said in a press release. “This new meaningful partnership comes just as our Plant 4 is fully completed early this month as we had previously committed and are on the move for future expansion into our second campus in order to provide our clients with even more flexible and advanced manufacturing technology.”
Pfizer’s chief global supply officer, executive vice president, Mike Dermott, added, “Pfizer is excited to continue our strategic partnership with Samsung Biologics Ltd. that aims to enable greater access to medicines for more patients across the world. This commitment is a reflection of Pfizer’s trust in the Korean Pharmaceutical industry to address emerging health challenges.”
Meanwhile, the partnership between Samsung Biologics and Pfizer has set a new record for the latter and the entire history of biopharma in South Korea. This is because it is the largest single contract to ever be recorded in the country.
Photo by: Samsung Biologics Newsroom
